Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.85 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159717 | 0.93 | FAAH (0.74) | FAAHPLA2G2AMAPTALDH1A1GAA | |
| SCHEMBL16839991 | 0.93 | FAAH (0.85) | FAAHPLA2G2AMAPTALDH1A1GAA | |
| SCHEMBL2159806 | 0.93 | FAAH (0.73) | FAAHPLA2G2AMAPTALDH1A1GAA | |
| SCHEMBL2168486 | 0.92 | FAAH (1.00) | FAAHPLA2G2AMAPTALDH1A1GAA | |
| SCHEMBL29392296 | 0.92 | FAAH (1.00) | FAAHPLA2G2AMAPTALDH1A1GAA | |
| SCHEMBL2169431 | 0.91 | FAAH (0.85) | FAAHPLA2G2AMAPTALDH1A1GAA | |
| SCHEMBL2197934 | 0.88 | FAAH (0.81) | FAAHPLA2G2AMAPTALDH1A1PKM | |
| SCHEMBL2159739 | 0.87 | FAAH (0.79) | FAAHPLA2G2AMAPTALDH1A1PKM | |
| SCHEMBL2169687 | 0.87 | FAAH (0.91) | FAAHPLA2G2AMAPTALDH1A1GAA | |
| SCHEMBL2159570 | 0.86 | FAAH (0.84) | FAAHPLA2G2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | claimed |
| WO-2014004676-A1 | USE OF FAAH INHIBITORS AS NEUROPROTECTIVE AGENTS IN THE CNS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-01-03 | — | — | WO | claimed |
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | claimed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | QUEST VENTURES LTD. (GB) | 2013-06-13 | — | — | US | claimed |
| WO-2011085216-A2 | USE OF FAAH INHIBITORS FOR TREATING PARKINSON'S DISEASE AND RESTLESS LEGS SYNDROME | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | claimed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | claimed |
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | QUEST VENTURES LTD. (GB) | 2013-06-13 | — | — | US | disclosed |
| WO-2011123719-A2 | USE OF FAAH INHIBITORS FOR TREATING ABDOMINAL, VISCERAL AND PELVIC PAIN | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011085216-A2 | USE OF FAAH INHIBITORS FOR TREATING PARKINSON'S DISEASE AND RESTLESS LEGS SYNDROME | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | FAAH, FAAH2, PNLIP | FAAH 1/4885PLA2G2A 26/4885MAPT 4229/4885 |
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | FAAH 109/4885PLA2G2A 3285/4885MAPT 997/4885 |
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | FAAH 1/4885PLA2G2A 242/4885MAPT 2737/4885 |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | FAAH, FAAH2, MGLL | FAAH 1/4885PLA2G2A 108/4885MAPT 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.